BRPI0511583A - performance-enhancing pharmaceutical compositions - Google Patents

performance-enhancing pharmaceutical compositions

Info

Publication number
BRPI0511583A
BRPI0511583A BRPI0511583-3A BRPI0511583A BRPI0511583A BR PI0511583 A BRPI0511583 A BR PI0511583A BR PI0511583 A BRPI0511583 A BR PI0511583A BR PI0511583 A BRPI0511583 A BR PI0511583A
Authority
BR
Brazil
Prior art keywords
polymers
pharmaceutical compositions
performance
hydroxypropyl methylcellulose
methylcellulose acetate
Prior art date
Application number
BRPI0511583-3A
Other languages
Portuguese (pt)
Inventor
Walter Christian Babcock
Dwayne Thomas Friesen
David Keith Lyon
Warren Kenyon Miller
Daniel Tod Smithey
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Priority claimed from PCT/IB2005/001580 external-priority patent/WO2005115330A2/en
Publication of BRPI0511583A publication Critical patent/BRPI0511583A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçõES FARMACêUTICAS COM DESEMPENHO AUMENTADO. São revelados polímeros de succinato do acetato de hidroxipropilmetilcelulose (HPMCAS) e acetato de hidroxipropilmetilcelulose (HPMCA) com graus de substituição únicos de grupos hidroxipropóxi, metóxi, acetil, e succinoil. Quando utilizados na fabricação de composições compreendendo um fármaco de baixa-solubilidade e tais polímeros, os polímeros provêem concentrações aquosas aumentadas e/ou estabilidade física melhorada.PHARMACEUTICAL COMPOSITIONS WITH INCREASED PERFORMANCE. Hydroxypropyl methylcellulose acetate succinate polymers (HPMCAS) and hydroxypropyl methylcellulose acetate (HPMCA) polymers with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups are disclosed. When used in the manufacture of compositions comprising a low solubility drug and such polymers, the polymers provide increased aqueous concentrations and / or improved physical stability.

BRPI0511583-3A 2004-05-28 2005-05-18 performance-enhancing pharmaceutical compositions BRPI0511583A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5755404P 2004-05-28 2004-05-28
US58654904P 2004-07-09 2004-07-09
PCT/IB2005/001580 WO2005115330A2 (en) 2004-05-28 2005-05-18 Pharmaceutical compositions with enhanced performance

Publications (1)

Publication Number Publication Date
BRPI0511583A true BRPI0511583A (en) 2008-01-02

Family

ID=38835092

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511583-3A BRPI0511583A (en) 2004-05-28 2005-05-18 performance-enhancing pharmaceutical compositions

Country Status (1)

Country Link
BR (1) BRPI0511583A (en)

Similar Documents

Publication Publication Date Title
ATE409462T1 (en) PHARMACEUTICAL COMPOSITIONS WITH IMPROVED PERFORMANCE CONTAINING AN HPMCA POLYMER
MX2012014849A (en) Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution.
DE602006014990D1 (en) INTRANASAL ADMINISTRATION OF FAST-ACTING INSULIN
BRPI0409133B8 (en) stable pharmaceutical preparations comprising methylnaltrexone
BRPI0509827A (en) pegylated nanoparticles for transporting biologically active molecules, pharmaceutical composition, lyophilizate constituting pegylated nanoparticles and preparation process for pegylated nanoparticles
EA200301250A1 (en) PHARMACEUTICAL COMPOSITIONS, CONTAINING LOW-Soluble And / Or Acid-Sensitive Drugs and Neutralized Acid Polymers
CY1111543T1 (en) NEW UNIONS
BR0113663A (en) Pectin Film Compositions
NO20075046L (en) Gastroresistant pharmaceutical formulations containing rifaximin
WO2007061360A3 (en) Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides
NO20065878L (en) Therapeutic compounds
UA102236C2 (en) Erythropoietin mimetic peptide derivatives and its pharmaceutical salt, the preparation and use thereof
BRPI0821004A8 (en) AMINOPYRAZOLE DERIVATIVE COMPOUND, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND USE OF IT
DK1543063T3 (en) Drug delivery
MX2007003648A (en) Hexafluoroisopropanol substituted ether derivatives.
BRPI0607413A2 (en) pharmaceutical composition comprising indolylmaleimide derivatives
BRPI0413094A (en) quinoline derivatives and their use in therapy
MX2008013040A (en) Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (cb1) receptor ligands.
BRPI0717369A2 (en) COMPOUND, MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
ATE386534T1 (en) ORAL PHARMACEUTICAL FORM CONTAINING PROBIOTIC BACTERIA
DE502007005902D1 (en) -METHYL-19-NOR-20-SPIROX-4-EN-3-ONE), as well as the PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF
UY29892A1 (en) NEW CHROMAN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
DK1987063T3 (en) Peptides and peptide derivatives, their preparation and their use in the preparation of a therapeutically and / or preventatively active pharmaceutical composition
SE0301701D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CL2008003230A1 (en) Tablet coating composition comprising cellulosic polymer, plasticizer, sweetener and powder flavor composition which comprises flavor associated with solid carrier; tablet coating fluid comprising said composition; pharmaceutical tablet; process of preparing said tablet.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired